

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,  
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

- Phone: +91-22-3982 9999 • Fax: 022-2495 2955
- Email: contact@alkem.com • Website: www.alkemlabs.com
- CIN: L00305MH1973PLC174201

22<sup>nd</sup> September, 2025

To,

**The Corporate Relationship Department  
BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001.  
*Scrip Code: 539523*

**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra East ,  
Mumbai 400 051.  
*Scrip Symbol: ALKEM*

**Sub: Press Release – Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer.**

Dear Sir(s)/Madam,

This is to intimate you that Alkem Laboratories Limited (the “Company”) launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer.

A press release in this regard is enclosed herewith.

Kindly take the same on record.

Sincerely,

For **Alkem Laboratories Limited**

**Manish Narang**

**President- Legal, Company Secretary and Compliance Officer**

## Press Release

### **Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer**

- *Alkem aims to expand access to treatment with its affordable pertuzumab biosimilar that meets global standards and is backed by trusted science*

**Mumbai, September 22, 2025:** Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, “Alkem” and its subsidiaries) today announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer.

Alkem’s Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab. In the pivotal phase 3 clinical trial, Alkem’s pertuzumab biosimilar, developed by its biotech subsidiary, demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator.

Accessibility of pertuzumab in India has remained a significant challenge and only limited HER2-positive breast cancer patients are able to use it in their treatment due to cost barriers. By bringing an affordable pertuzumab biosimilar, backed by research, regulatory-compliant manufacturing, and strong oncology distribution network, Alkem strives to ensure scientific credibility and improved accessibility.

*“Breast cancer is the most common cancer among Indian women, and addressing its growing burden requires treatments that are effective, accessible and affordable. Oncology is a priority area for Alkem, and our efforts are focused on developing treatment options that combine scientific excellence with wider access. The launch of Pertuza reflects this commitment and further strengthens our oncology portfolio. Alkem aims to make this critical therapy available to thousands of women each year who would otherwise be excluded,” said Dr. Vikas Gupta, Chief Executive Officer, Alkem.*

Alkem has a growing portfolio of oncology drugs with key products being cetuximab biosimilar, denosumab biosimilar, bevacizumab biosimilar, and romiplostim biosimilar, among others.

**About Alkem:**

Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 50 years in providing high quality medicines to patients. It is the fifth largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 19 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centers across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has meaningful presence in the US, Latin America, Australia and several Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit [www.alkemlabs.com](http://www.alkemlabs.com) and follow us on [LinkedIn](#), [Instagram](#), [Facebook](#).

<b>Contacts</b>
-----------------

<p><b>Media:</b> Isha Trivedi <a href="mailto:alkemcorpcomm@alkem.com">alkemcorpcomm@alkem.com</a> +91-98925 90003</p>	<p><b>Investors:</b> Purvi Shah <a href="mailto:purvi.shah@alkem.com">purvi.shah@alkem.com</a> +91-84337 00890</p>
--	--